Alto Neuroscience Inc(ANRO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:01 PM ET (Korea 10/31 05:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.47 | Insider Own | 9.4% | Shs Outstand | 39.2M | Perf Week | 2.87% |
| Market Cap | 0.89B | Forward P/E | - | EPS next Y | -7.91% | Insider Trans | -3.53% | Shs Float | 35.5M | Perf Month | -10.71% |
| Enterprise Value | 0.67B | PEG | - | EPS next Q | -0.67 | Inst Own | 79.65% | Short Float | 14.64% | Perf Quarter | -17.13% |
| Income | -0.08B | P/S | - | EPS this Y | -27.18% | Inst Trans | 6.42% | Short Ratio | 9.33 | Perf Half Y | -9.38% |
| Sales | 0.00B | P/B | 3.62 | EPS next 5Y | -10.92% | ROA | -40.9% | Short Interest | 5.20M | Perf YTD | 26.97% |
| Book/sh | 6.25 | P/C | 3.64 | EPS past 3/5Y | -26.47% -57.17% | ROE | -49.17% | 52W High | -39.7% ($37.48) | Perf Year | 57.82% |
| Cash/sh | 6.21 | P/FCF | - | Sales past 3/5Y | - | ROIC | -35.48% | 52W Low | 121.57% ($10.20) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -3.04% | Gross Margin | - | Volatility(W/M) | 5.12% 6.38% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.51 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.85 | EPS Q/Q | 1.28% | Profit Margin | - | RSI (14) | 39.66 | Recom | 1.27 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.85 | Sales Q/Q | - | SMA20 | -2.07% ($23.08) | Beta | 1.36 | Target Price | $38.88 |
| Payout | - | Debt/Eq | 0.11 | Earnings | 2026/8/12 | SMA50 | -20.07% ($28.27) | Rel Volume | 0.87 | Prev Close | $23.47 |
| Employees | 68 | LT Debt/Eq | 0.08 | EPS/Sales Surpr. | 11.5% - | SMA200 | -6.82% ($24.25) | Avg Volume(3M) | 0.56M | Price | $22.6 |
| IPO | 2024/2/2 | Option/Short | Yes/Yes | Trades | 4931 | Volume | 484,432 | Change | -3.71% |
🧠 Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing treatments for neuropsychiatric disorders, including depression. Leveraging a precision medicine platform that analyzes multi-modal data—such as EEG and biomarkers—the company identifies patient-specific drug candidates with a higher likelihood of response, and develops its pipeline accordingly. Its data-driven approach, aimed at improving clinical success rates, is the company's key differentiator.
Over the past 1 year, roughly in the middle
40% below its 1-year high.
Traded about as much as usual. That is 87% of its average volume.
ANRO has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -27.2% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 79.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #168 of 597 in the industry
Based on market cap of $887M.
ALMS#166 Alumis Inc $898M PER - 
JBIO#167 Jade Biosciences Inc $894M PER - ANRO#168 Alto Neuroscience Inc $887M PER - 
AKTS#169 Aktis Oncology Inc $886M PER - 
IVA#170 Inventiva ADR $868M PER - 
FAQ
What kind of company is ANRO?
ANRO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ANRO?
The market cap of ANRO is approximately $887M, ranking 2,669 within its sector.
What is the 52-week high and low for ANRO?
ANRO has recorded a 52-week high of $37.48 and a low of $10.20.
